PE20210658A1 - Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- PE20210658A1 PE20210658A1 PE2020001164A PE2020001164A PE20210658A1 PE 20210658 A1 PE20210658 A1 PE 20210658A1 PE 2020001164 A PE2020001164 A PE 2020001164A PE 2020001164 A PE2020001164 A PE 2020001164A PE 20210658 A1 PE20210658 A1 PE 20210658A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- ghrelin
- goat
- inhibitors
- aciltransferase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title abstract 2
- 102000012004 Ghrelin Human genes 0.000 title 1
- 101800001586 Ghrelin Proteins 0.000 title 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 abstract 2
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 abstract 2
- HFBUHBUXTXXZBB-UHFFFAOYSA-N 6-[[5-bromo-6-(4-fluoropyrazol-1-yl)pyridin-2-yl]methyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine Chemical compound BrC=1C=CC(=NC=1N1N=CC(=C1)F)CC=1C(=NC=2N(C=1N)N=CN=2)C HFBUHBUXTXXZBB-UHFFFAOYSA-N 0.000 abstract 1
- KFWWNQJTSKPASP-UHFFFAOYSA-N 6-[[6-bromo-5-(difluoromethoxy)pyridin-2-yl]methyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine Chemical compound BrC1=C(C=CC(=N1)CC=1C(=NC=2N(C=1N)N=CN=2)C)OC(F)F KFWWNQJTSKPASP-UHFFFAOYSA-N 0.000 abstract 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a compuestos derivados de triazolopirimidina de formula general (I); en donde R1 es Cl, Br, CN o CH3; R2 es fenilo o piridinilo cada uno de los cuales esta sustituido con un sustituyente R3 que contiene fluor, donde R3 es seleccionado de C1-6-alquilo, 3-7-cicloalquilo, -O-(C1-6-alquilo), entre otros; cada uno sustituido con uno o mas F. Un compuesto seleccionado es 6-{[6-bromo-5-(difluorometoxi)piridin-2-il]metil}-5-metil-[1,2,4]triazolo[1,5-a]pirimidin-7-amina, 6-{[5-bromo-6-(4-fluoro-1H-pirazol-1-il)piridin-2-il]metil}-5-metil-[1,2,4]triazolo[1,5-a]pirimidin-7-amina. Dichos compuestos son inhibidores de la ghrelin O-aciltransferasa (GOAT). Tambien refiere una composicion farmaceutica que comprende dicho compuesto, siendo adecuada para la profilaxis y/o el tratamiento de enfermedades metabolicas, en particular, obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154831 | 2018-02-02 | ||
| PCT/EP2019/051994 WO2019149660A1 (en) | 2018-02-02 | 2019-01-28 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210658A1 true PE20210658A1 (es) | 2021-03-31 |
Family
ID=61157054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001164A PE20210658A1 (es) | 2018-02-02 | 2019-01-28 | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11583532B2 (es) |
| EP (1) | EP3746443B1 (es) |
| JP (1) | JP7083397B2 (es) |
| KR (1) | KR20200118125A (es) |
| CN (1) | CN111683951B (es) |
| AU (1) | AU2019215710A1 (es) |
| BR (1) | BR112020014436A2 (es) |
| CA (1) | CA3087925A1 (es) |
| CL (1) | CL2020001909A1 (es) |
| CO (1) | CO2020009177A2 (es) |
| CR (1) | CR20200329A (es) |
| EA (1) | EA202091803A1 (es) |
| EC (1) | ECSP20050797A (es) |
| IL (1) | IL276145A (es) |
| JO (1) | JOP20200187A1 (es) |
| MA (1) | MA51774A (es) |
| MX (1) | MX2020007994A (es) |
| PE (1) | PE20210658A1 (es) |
| PH (1) | PH12020551170A1 (es) |
| SG (1) | SG11202006302TA (es) |
| WO (1) | WO2019149660A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037277B1 (ru) | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
| JOP20200187A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| TW202202502A (zh) * | 2020-03-26 | 2022-01-16 | 美商斯諾皮亞生物科學公司 | 經同位素標記之曲匹地(trapidil)衍生物 |
| EP4146344A1 (en) | 2020-05-04 | 2023-03-15 | Volastra Therapeutics, Inc. | Imino sulfanone inhibitors of enpp1 |
| DK4153600T3 (da) | 2020-05-22 | 2024-10-21 | Boehringer Ingelheim Int | Kontinuerlig fremgangsmåde til fremstilling af alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat |
| DK4153599T3 (da) | 2020-05-22 | 2024-06-17 | Boehringer Ingelheim Int | Fremgangsmåde til at fremstille alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat |
| US12091412B2 (en) * | 2020-06-16 | 2024-09-17 | Volastra Therapeutics, Inc. | Heterocyclic inhibitors of ENPP1 |
| CN115073363B (zh) * | 2022-06-16 | 2024-01-26 | 宁波申泰生物科技有限公司 | 一种5-氟-2-甲氧基烟醛及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3338292A1 (de) * | 1983-10-21 | 1985-05-02 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)-pyrimidine und diese enthaltende fungizide |
| JP2002249492A (ja) | 2000-12-22 | 2002-09-06 | Nippon Bayer Agrochem Co Ltd | トリアゾロピリミジン類 |
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| WO2006114405A2 (de) | 2005-04-25 | 2006-11-02 | Basf Aktiengesellschaft | Verwendung von 5-alkyl-6-phenylalkyl-7-amino-azolopyrimidinen, neue azolopyrimidine, verfahren zu ihrer herstellung und sie enthaltende mittel |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| DK3567035T3 (da) | 2007-04-11 | 2022-09-05 | Canbas Co Ltd | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer |
| CA2685524A1 (en) * | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| CA2687611A1 (en) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| AU2008365555B2 (en) | 2008-12-15 | 2016-01-14 | Zealand Pharma A/S | Glucagon analogues |
| MX2011006320A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
| KR20110126592A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| HK1200369A1 (en) | 2011-12-23 | 2015-10-09 | Zealand Pharma A/S | Glucagon analogues |
| CN104254525B (zh) * | 2012-02-24 | 2016-05-25 | 武田药品工业株式会社 | 芳环化合物 |
| US9492448B2 (en) | 2012-06-20 | 2016-11-15 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| JP6615896B2 (ja) | 2015-01-30 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロン合成酵素阻害剤 |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| CA3002831C (en) | 2015-10-22 | 2024-04-16 | Cavion, Inc. | Methods for treating angelman syndrome and related disorders |
| EA037277B1 (ru) | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
| WO2018044663A1 (en) | 2016-08-29 | 2018-03-08 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| JOP20200187A1 (ar) * | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
| AU2019215709A1 (en) | 2018-02-02 | 2020-07-16 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
-
2019
- 2019-01-28 JO JOP/2020/0187A patent/JOP20200187A1/ar unknown
- 2019-01-28 WO PCT/EP2019/051994 patent/WO2019149660A1/en not_active Ceased
- 2019-01-28 CN CN201980010417.7A patent/CN111683951B/zh active Active
- 2019-01-28 US US16/966,493 patent/US11583532B2/en active Active
- 2019-01-28 KR KR1020207025419A patent/KR20200118125A/ko not_active Withdrawn
- 2019-01-28 CA CA3087925A patent/CA3087925A1/en not_active Abandoned
- 2019-01-28 MA MA051774A patent/MA51774A/fr unknown
- 2019-01-28 MX MX2020007994A patent/MX2020007994A/es unknown
- 2019-01-28 SG SG11202006302TA patent/SG11202006302TA/en unknown
- 2019-01-28 PE PE2020001164A patent/PE20210658A1/es unknown
- 2019-01-28 AU AU2019215710A patent/AU2019215710A1/en not_active Abandoned
- 2019-01-28 EA EA202091803A patent/EA202091803A1/ru unknown
- 2019-01-28 EP EP19702247.8A patent/EP3746443B1/en active Active
- 2019-01-28 CR CR20200329A patent/CR20200329A/es unknown
- 2019-01-28 JP JP2020541900A patent/JP7083397B2/ja active Active
- 2019-01-28 BR BR112020014436-3A patent/BR112020014436A2/pt not_active Application Discontinuation
-
2020
- 2020-07-19 IL IL276145A patent/IL276145A/en unknown
- 2020-07-21 CL CL2020001909A patent/CL2020001909A1/es unknown
- 2020-07-24 CO CONC2020/0009177A patent/CO2020009177A2/es unknown
- 2020-07-31 PH PH12020551170A patent/PH12020551170A1/en unknown
- 2020-08-24 EC ECSENADI202050797A patent/ECSP20050797A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3746443B1 (en) | 2022-07-06 |
| US11583532B2 (en) | 2023-02-21 |
| WO2019149660A1 (en) | 2019-08-08 |
| CN111683951B (zh) | 2023-10-13 |
| CL2020001909A1 (es) | 2020-10-30 |
| IL276145A (en) | 2020-09-30 |
| CR20200329A (es) | 2020-09-04 |
| ECSP20050797A (es) | 2020-09-30 |
| JP7083397B2 (ja) | 2022-06-10 |
| EP3746443A1 (en) | 2020-12-09 |
| CN111683951A (zh) | 2020-09-18 |
| EA202091803A1 (ru) | 2020-12-16 |
| KR20200118125A (ko) | 2020-10-14 |
| JOP20200187A1 (ar) | 2020-07-29 |
| SG11202006302TA (en) | 2020-07-29 |
| JP2021512115A (ja) | 2021-05-13 |
| BR112020014436A2 (pt) | 2020-12-01 |
| PH12020551170A1 (en) | 2021-05-31 |
| AU2019215710A1 (en) | 2020-07-23 |
| CA3087925A1 (en) | 2019-08-08 |
| US20210038603A1 (en) | 2021-02-11 |
| MX2020007994A (es) | 2020-09-09 |
| MA51774A (fr) | 2021-05-12 |
| CO2020009177A2 (es) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210658A1 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| PE20110828A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak | |
| MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| AR112833A2 (es) | Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20190918A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20141059A1 (es) | Indazoles | |
| PE20120107A1 (es) | Inhibidores de proteina cinasa | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20161388A1 (es) | Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos |